18/01/2023

Cape Town-based biotechnology company, Afrigen, appoints new board chair

We are very proud to announce that our Chairman and Board Member, Mr. Levent Selamoglu has been appointed as Chairman of Afrigen Biologics.  Afrigen is a leading biotechnology company based in Cape Town, South Africa.  The company is focused on product development, bulk adjuvant manufacturing and distribution of key biologicals […]
27/12/2022

Zdravlje (Frontier Biopharma) and Adalvo Sign Licensing & Supply Agreement for Central & Eastern Europe

Zdravlje / Frontier Biopharma (“Frontier”) and  Adalvo are pleased to announce their collaboration in several therapeutic areas for the markets of Central and Eastern Europe and the Balkans. Over the next months and years, this collaboration will extend Frontier’s commercial and therapeutic footprint with a basket of more than 30 molecules from Adalvo’s advanced […]
13/12/2022

Zdravlje Leskovac Awarded for Successful Business in 2022 by the Chamber of Commerce and Industry of Serbia

We are proud to announce that Zdravlje Leskovac has received the Award for Successful Business in 2022 by the Chamber of Commerce and Industry of Serbia. At the Ceremony held on 9 December, the Chamber of Commerce and Industry of Serbia awarded the traditional Annual Awards to the most successful […]
29/09/2022

Zdravlje Leskovac at “Serbia Business Run” in Belgrade

We work, run, enjoy TOGETHER Zdravlje Leskovac participated for the first time on September 29. at the great “Serbia Business Run“ in Belgrade. This manifestation, which aims to promote healthy lifestyles and running as a great way of recreation for the modern working person, is a series of 5 km […]
01/09/2022

Tsvetomir Yordanov joins Zdravlje Leskovac as Group Business Development Director

Zdravlje is pleased to announce that as of 1st September 2022, Mr. Tsvetomir Yordanov has joined our senior management team as Group Business Development Director, directly reporting to Kiren Naidoo (CEO). Tsvetomir graduated in International Business and holds a master’s degree in Public Finance from the UNWE (Economics University), Sofia, Bulgaria. […]
18/08/2022

Zdravlje receives an EU Wholesale Distribution Authorization by BDA

We are pleased to announce that as of 16 August Zdravlje Pharmaceuticals (Bulgaria), a subsidiary of Zdravlje Leskovac, has received a Wholesale Distribution Authorization by the Bulgarian Drug Agency (BDA). “This is an important step for both our Commercial and Contract Development and Manufacturing (CDMO) business lines as we are […]
17/08/2022

The ALIMS Approves Regkirona for Serbia with Zdravlje AD Leskovac as MA Holder

The Serbian Agency for Medicines (ALIMS) has approved on 02.08.2022 the Marketing Authorisation for Regkirona (regdanvimab) for Serbia with Zdravlje AD Leskovac as the Marketing Authorisation Holder. Regkirona was one of the first monoclonal antibody medicines thar received The European Medicines Agency (EMA)’s authorisation on 12.11.2021 following a positive opinion […]
08/08/2022

Milan Markicevic joins Zdravlje Leskovac as Group Finance Director

Zdravlje is pleased to announce that as of 1st August 2022, Mr. Milan Markicevic has joined our senior management team as Group Finance Director, directly reporting to Kiren Naidoo (CEO). Milan holds a master’s degree at the Faculty of Economics of the University of Belgrade, strategic financial management module and […]
21/07/2022

Successful visit supporting the World Pharmacy Students Exchange Program

As part of the World Exchange Program of Pharmacy and Pharmaceutical Sciences Students (SEP) and the International Pharmacy Students Federation (IPSF) project, which this year marks the 70th anniversary of the first successfully held exchange, Zdravlje, in coordination with the National Association of Pharmacy Students of Serbia, realized a visit […]
17/03/2022

Zdravlje A.D. Signs License Agreement with Medicines Patent Pool for nirmatrelvir

Belgrade, Serbia 17 March 2022 –– Zdravlje A.D. (Zdravlje) announces the signing of a license agreement with the Medicines Patent Pool (MPP) for a generic version of nirmatrelvir, the novel oral COVID-19 antiviral medicine (PF-07321332) developed by Pfizer, which is administered in combination with low dose ritonavir (PF-07321332; ritonavir). This […]